Skip to main content
Psych Congress  
2017

RE-KINECT: A Prospective Real-World Dyskinesia Screening Study and Registry in Patients Taking Antipsychotic Agents: Patient Demographics

Authors  
Andrew Cutler, MD; Stanley Caroff, MD; Caroline Tanner, MD, PhD; William Lenderking, PhD; Karen Yeomans, BSc; Huda Shalhoub, PhD; Linda Ross, MPH; Chuck Yonan, PharmD
Sponsor  
Neurocrine Biosciences, Inc.

This poster was presented at the 30th annual  Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.

Background: Tardive dyskinesia (TD) is associated with prolonged exposure to dopamine receptor blockers, including antipsychotics. This prospective registry study describes the presence and impact of involuntary movements (possible TD) in a real-world population.

Methods: RE-KINECT (NCT03062033) has a target sample size of ~1,000 patients from _70 US psychiatric practices. Outpatients (≥18 years) with ≥3 months lifetime exposure to antipsychotic(s) and ≥1 psychiatric disorder are eligible for screening, which involves a clinician observation of abnormal involuntary movements in general body regions (head/face, neck/trunk, upper/lower limbs) and confirmation of possible TD. Based on clinician assessment, patients are assigned to Cohort 2 or Cohort 1 (with or without abnormal involuntary movements, respectively). In both cohorts, the following baseline assessments are included: clinician's assessment of clinical psychiatric severity, patient perceived health-related quality of life (EuroQOL 5-Dimensions), social burden/disability questionnaire (Sheehan Disability Scale), and 12-month retrospective chart review of medical and treatment history. Cohort 2 will also participate in a 12-month longitudinal evaluation. Interim baseline data are available from 3 active sites.

Results: Recruitment is ongoing. Baseline chart review data is available for 116 patients-mean age, 49.6 years; male, 40%; schizophrenia/schizoaffective disorder, 32.8%; mood disorder, 84.5%-with 10.4 years mean cumulative lifetime exposure to antipsychotic(s). 35.3% of subjects had clinically observed TD symptoms. Updated results will be presented at the meeting.

Conclusion: This novel registry aims to evaluate the real-world potential impact/burden of TD. Preliminary analysis describes the prevalence of possible TD and functional impact of the condition.

Back to Top